NasdaqCM:ORGS

Stock Analysis Report

Executive Summary

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Orgenesis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.1%

ORGS

0.8%

US Biotechs

0.6%

US Market


1 Year Return

-42.2%

ORGS

-9.3%

US Biotechs

6.2%

US Market

Return vs Industry: ORGS underperformed the US Biotechs industry which returned -9.3% over the past year.

Return vs Market: ORGS underperformed the US Market which returned 6.2% over the past year.


Share holder returns

ORGSIndustryMarket
7 Day-0.1%0.8%0.6%
30 Day-19.2%-3.8%-1.8%
90 Day-13.9%-3.4%-2.0%
1 Year-42.2%-42.2%-8.5%-9.3%8.6%6.2%
3 Year-25.3%-25.3%13.5%9.6%45.7%36.3%
5 Year-49.0%-49.0%5.6%0.4%68.5%50.0%

Price Volatility Vs. Market

How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orgenesis undervalued based on future cash flows and its price relative to the stock market?

1.94x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: ORGS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ORGS is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate ORGS's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: ORGS is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Orgenesis expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

22.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: ORGS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORGS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORGS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORGS's revenue (45.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ORGS's revenue (45.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if ORGS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Orgenesis performed over the past 5 years?

-28.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ORGS is unprofitable, and losses have increased over the past 5 years at a rate of -28% per year.

Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: ORGS has a negative Return on Equity (-36.18%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ORGS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ORGS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Orgenesis's financial position?


Financial Position Analysis

Short Term Liabilities: ORGS's short term assets ($30.3M) exceeds its short term liabilities ($17.1M)

Long Term Liabilities: ORGS's short term assets ($30.3M) exceeds its long term liabilities ($5.5M)


Debt to Equity History and Analysis

Debt Level: ORGS's debt to equity ratio (7.1%) is considered satisfactory

Reducing Debt: ORGS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: ORGS has a low level of unsold assets or inventory.

Debt Coverage by Assets: ORGS's debt is covered by short term assets (assets are 8.133420x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ORGS has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ORGS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Orgenesis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate ORGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ORGS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ORGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Orgenesis's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Vered Caplan (50yo)

5.8yrs

Tenure

US$1,975,590

Compensation

Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs. Market: Vered's total compensation ($USD1.98M) is about average for companies of similar size in the US market ($USD495.85K).

Compensation vs Earnings: Vered's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.0yrs

Average Tenure

50yo

Average Age

Experienced Management: ORGS's management team is considered experienced (3 years average tenure).


Board Age and Tenure

6.4yrs

Average Tenure

54yo

Average Age

Experienced Board: ORGS's board of directors are considered experienced (6.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,50008 Jan 19
Hugues Bultot
EntityIndividual
Shares300
Max PriceUS$5.00

Ownership Breakdown


Management Team

  • Neil Reithinger (49yo)

    CFO, Secretary & Treasurer

    • Tenure: 5.2yrs
    • Compensation: US$406.04k
  • Vered Caplan (50yo)

    Chairperson of the Board

    • Tenure: 5.8yrs
    • Compensation: US$1.98m
  • Darren Head (52yo)

    Chief Executive Officer of Masthercell Global

    • Tenure: 0.8yrs
  • Sarah Ferber (65yo)

    Founder & Chief Scientific Officer

    • Tenure: 0yrs
    • Compensation: US$268.78k
  • Denis Bedoret (38yo)

    President of Masthercell Global

    • Tenure: 0.8yrs
    • Compensation: US$288.60k

Board Members

  • Guy Yachin (51yo)

    Independent Director

    • Tenure: 7.5yrs
    • Compensation: US$230.77k
  • Jay Skyler (72yo)

    Scientific Advisor

    • Tenure: 6.5yrs
    • Compensation: US$9.41k
  • David Sidransky (59yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$119.73k
  • Itamar Raz (71yo)

    • Tenure: 4.6yrs
  • Vered Caplan (50yo)

    Chairperson of the Board

    • Tenure: 5.8yrs
    • Compensation: US$1.98m
  • Yaron Adler (48yo)

    Independent Director

    • Tenure: 7.5yrs
    • Compensation: US$90.16k
  • Zan Fleming

    Scientific Advisor

    • Tenure: 7.5yrs
    • Compensation: US$67.20k
  • Camillo Ricordi

    Scientific Advisor

    • Tenure: 6.9yrs
    • Compensation: US$8.96k
  • Ashish Nanda (54yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$17.28k
  • Lorenzo Piemonti

    Member Scientific Advisory Board

    • Tenure: 1.5yrs

Company Information

Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orgenesis Inc.
  • Ticker: ORGS
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$59.237m
  • Shares outstanding: 16.14m
  • Website: https://www.orgenesis.com

Number of Employees


Location

  • Orgenesis Inc.
  • 20271 Goldenrod Lane
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORGSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009

Biography

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development serv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 01:15
End of Day Share Price2019/10/11 00:00
Earnings2018/11/30
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)